The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The importance of cardio-oncology in CLL
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, highlights the importance of cardio-oncology for hematological malignancies, focusing on his experience in patients with chronic lymphocytic leukemia (CLL). Assessing patients’ cardiovascular status prior to and during treatment with a BTK inhibitor (BTKi) allows for cardiovascular toxicities to be managed and the risk of mortality from these complications to be reduced. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
